Figure 1.
Individual IBD patients with chronic active disease refractory to conventional medications. Patients in clinical and endoscopic remission secondary to selective apheresis treatment. Follow-up time in months.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.